Prevention of Pneumonia Comparing Ceftriaxone With Subglottic Aspiration
Launched by HOSPITAL UNIVERSITARIO PRINCIPE DE ASTURIAS · Sep 11, 2006
Trial Information
Current as of June 02, 2025
Completed
Keywords
ClinConnect Summary
Background: In a previous double-blind, placebo-controlled, randomized trial we found that a 3-day-course of ceftriaxone significantly reduced the incidence of early-onset ventilator-associated pneumonia (EOP). Continuous aspiration of secretions accumulating in the subglottic space above the cuff of the endotracheal tube has also been shown to prevent EOP.
Objective: To compare the effect of both preventive measures on the incidence of EOP.
Design: Randomized, multicenter.
Setting: Three general intensive care units at university hospitals in Spain. Patients: Patients without signs of i...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Endotracheal intubation with endotracheal tube equipped with port for aspirations of subglottic contents and expected to exceed 48 hors.
- • Absence of infection.
- • 18 years or older.
- • Informed Consent.
- Exclusion Criteria:
- • Endotracheal intubation prior to admission to hospital.
- • Allergic to beta-lactam antibiotics.
- • Formal indication for systemic antibiotic therapy.
About Hospital Universitario Principe De Asturias
Hospital Universitario Príncipe de Asturias is a leading healthcare institution in Spain, renowned for its commitment to advanced medical research and clinical excellence. As a prominent clinical trial sponsor, the hospital integrates cutting-edge scientific innovation with patient-centered care, facilitating a diverse range of clinical studies aimed at improving health outcomes. With a multidisciplinary team of experienced researchers and healthcare professionals, the hospital emphasizes ethical standards and regulatory compliance, ensuring the safety and welfare of trial participants while contributing to the advancement of medical knowledge and treatment options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Alcala De Henares, Madrid, Spain
Getafe, Madrid, Spain
Barcelona, , Spain
Patients applied
Trial Officials
Miguel Sanchez, MD, PhD
Principal Investigator
Hospital Universitario Principe de Asturias
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials